The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi Comprehensive Cancer Center, Division of Hematology and Oncology, Medstar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, USA.
Department of Internal Medicine, Medstar Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, USA.
Curr Oncol. 2022 Sep 23;29(10):6864-6892. doi: 10.3390/curroncol29100541.
Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients.
胰腺腺癌仍然是全球最致命的癌症之一，因此非常需要改进治疗方案。虽然近年来免疫检查点抑制剂的免疫疗法的突破极大地改变了其他恶性肿瘤的治疗模式，因为这些疗法显著提高了患者的生存率，但对于胰腺癌来说并非如此。具有适度疗效的化疗仍然是晚期胰腺癌治疗的基石。胰腺肿瘤是天生的免疫冷肿瘤，在临床试验中对免疫疗法大多具有抗性。通过阐明耐药机制和开发新的治疗方法来理解和克服免疫疗法的当前失败，对于利用免疫调节疗法在胰腺癌症患者中获得持久的疗效至关重要。
